<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04050358</url>
  </required_header>
  <id_info>
    <org_study_id>Basis-HIIT</org_study_id>
    <nct_id>NCT04050358</nct_id>
  </id_info>
  <brief_title>Effect of Basis™ and High Intensity Interval Training (HIIT) on Muscle Metabolism and Exercise Performance</brief_title>
  <official_title>The Effect of Basis™ and High Intensity Interval Training (HIIT) on Muscle Metabolism and Exercise Performance in Healthy 18 - 35 Year Olds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elysium Health</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Exeter</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Elysium Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, randomized, placebo-controlled pilot study to evaluate the effects
      of high intensity interval training (HIIT) and daily administration of BasisTM for 3 weeks,
      in 18-35 year old males.

      The study will consist of a screening visit, baseline visit, followed by treatment and HIIT
      phase (3 weeks) and a post-supplementation, follow-up visit (this will occur 48 h (or more)
      after the final HIIT session). Following the screening phase, subjects who meet entry
      criteria will be randomly assigned to 1 of 2 treatment groups: recommended dose of BasisTM
      (250 mg Nicotinamide Riboside and 50 mg Pterostilbene) per day or matching-placebo in a 1:1
      ratio.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2020</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mitochondrial function</measure>
    <time_frame>3 weeks</time_frame>
    <description>Measured via high-resolution respirometry using the Oroboros Oxygraph</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exercise Capacity</measure>
    <time_frame>3 weeks</time_frame>
    <description>To measure maximal endurance capacity measured via VO2max</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength</measure>
    <time_frame>3 weeks</time_frame>
    <description>To measure maximal voluntary contraction using a force transducer strength chair</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle power</measure>
    <time_frame>3 weeks</time_frame>
    <description>Determine the effects of HIIT with and without NRPT supplementation on muscle power producing capabilities measured by the 30 second Wingate test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitochondrial proteins</measure>
    <time_frame>3 weeks</time_frame>
    <description>To determine whether HIIT with NRPT supplementation improves mitochondrial function more so than HIIT alone, using Western blotting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass</measure>
    <time_frame>3 weeks</time_frame>
    <description>To determine the effects of HIIT with and without NRPT supplementation on body composition by measuring body mass using a bioelectrical impedance analysis scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Body Fat</measure>
    <time_frame>3 weeks</time_frame>
    <description>To determine the effects of HIIT with and without NRPT supplementation on body composition by measuring percent body fat using a bioelectrical impedance analysis scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery via POMS</measure>
    <time_frame>3 weeks</time_frame>
    <description>To determine the effects of HIIT with and without NRPT supplementation on recovery via profile of mood states (POMS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery via RESTQ</measure>
    <time_frame>3 weeks</time_frame>
    <description>To determine the effects of HIIT with and without NRPT supplementation on recovery via recovery stress (RESTQ) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity levels using FitBit</measure>
    <time_frame>3 weeks</time_frame>
    <description>To characterize volunteer's habitual physical activity levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height</measure>
    <time_frame>3 weeks</time_frame>
    <description>Measure height using a stadiometer, to characterize demographics of recruited volunteers the recruited volunteers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>3 weeks</time_frame>
    <description>Measure blood pressure using Dinamap Pro monitor to characterize demographics of recruited volunteers the recruited volunteers</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1X dose of NRPT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>NRPT</intervention_name>
    <description>Subjects randomly assigned to the active group will receive Nicotinamide Riboside and Pterostilbene (each capsule contains 125 mg NR and 25 mg PT, total daily dose is 2 capsules) for 3 weeks</description>
    <arm_group_label>1X dose of NRPT</arm_group_label>
    <other_name>BasisTM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Subjects randomly assigned to the Placebo group will receive placebo oral capsules for 3 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 35 year old males

          -  Body mass index between 18.5-30 kg.m-2

          -  Ability to give informed consent

          -  Recreationally active (defined in the present study as exercising once a week or
             more).

        Exclusion Criteria:

          -  Those regularly conducting HIIT or highly trained in endurance events (e.g.
             triathlete)

          -  Currently taking supplements known to affect metabolism (e.g. ibuprofen, stimulants,
             vitamins, NR)

          -  Taking prescribed medication

          -  Consuming a vegan diet

          -  Consuming a high fat, low carbohydrate diet

          -  Habitual consumption of protein and/or dairy supplements (e.g. whey protein)

          -  Smokers
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Etheridge, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Exeter</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Colleen Deane, PhD</last_name>
    <phone>01392 722882</phone>
    <email>c.s.deane@exeter.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Craig Williams</last_name>
    <email>cw436@exeter.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Exeter</name>
      <address>
        <city>Exeter</city>
        <zip>EX1 2LU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Craig Williams</last_name>
      <email>cw436@exeter.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Timothy Etheridge, PhD, FHEA</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Colleen Deane, PhD., AFHEA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 6, 2019</study_first_submitted>
  <study_first_submitted_qc>August 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2019</study_first_posted>
  <last_update_submitted>January 3, 2020</last_update_submitted>
  <last_update_submitted_qc>January 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

